Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2020-06-09 Capital/Financing Update
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 4, 2020, by Menlo Therapeutics Inc. It reports the entry into a material definitive agreement, specifically an underwriting agreement for a public offering of common stock shares. The document includes details about the offering price, number of shares, and closing date. It also references exhibits such as the underwriting agreement and legal opinion. The content focuses on a financing transaction and capital raising activity. Given the nature of the filing and the detailed description of the underwriting agreement and share offering, this document fits the category of Capital/Financing Update (CAP). The document length is 5307 characters, which is sufficient to contain substantive information rather than just an announcement. Therefore, the classification is CAP with high confidence.
2020-06-09 English
424B2
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(2) under the Securities Act, related to a public offering of common stock by Menlo Therapeutics Inc. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and other legal and financial disclosures typical of a prospectus supplement. The document is not a financial report, earnings release, or management discussion, but rather a capital raising disclosure document. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, underwriting details, and risk disclosures, confirming it is a full prospectus supplement rather than a brief announcement or regulatory filing. Hence, the classification is CAP with high confidence.
2020-06-05 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement and accompanying prospectus for a securities offering by Menlo Therapeutics Inc. It includes sections such as 'Prospectus Supplement Summary,' 'The Offering,' 'Risk Factors,' 'Use of Proceeds,' and detailed descriptions of the securities being offered. It references a shelf registration statement on Form S-3 and discusses the terms of the offering, underwriting, and use of proceeds. This type of document is a capital markets filing related to fundraising and issuance of common stock. It is not an annual or quarterly report, audit report, earnings release, or any other type of report. It is clearly a Capital/Financing Update as it provides detailed information about a new stock offering and related financing activities.
2020-06-04 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions that the filing includes an Investor Presentation (Exhibit 99.1) used at a virtual healthcare conference. The document is relatively short (3540 characters) and primarily serves to file the presentation as an exhibit rather than containing the full presentation text or detailed financial data. According to the rules, when a document is short and references an attached presentation, it should be classified as an Investor Presentation (IP).
2020-06-02 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes an announcement of a press release about positive Phase 2 clinical trial results and an attached investor presentation. The document does not contain full financial statements or detailed financial analysis but rather announces events and provides exhibits. The presence of an investor presentation as an exhibit suggests the document is primarily an announcement of events and materials rather than the materials themselves. The document length is 4030 characters, which is relatively short and consistent with an 8-K current report. Therefore, the filing type is best classified as Regulatory Filings (RNS), which is the fallback category for miscellaneous filings like Form 8-K that do not fit other specific categories.
2020-06-02 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an FDA approval event and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, and the document is relatively short (3750 characters). It is an announcement of a significant corporate event rather than a financial report or earnings release. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-05-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.